Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan-Reference-Cited by-同舟云学术

Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan

Published:2023-09-12 Issue:1 Volume:26 Page:1122-1133
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Mizuoka Takashi¹^ORCID,Sakamaki Hiroyuki²,Fuji Shigeo³^ORCID,Saito Shota⁴,Murata Tatsunori⁴,Ohno Shinya¹^ORCID,Inubashiri Naoki¹^ORCID,Oshima Tomoha¹^ORCID,Yamamoto Kazuhito⁵^ORCID

Affiliation:

1. Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan

2. Graduate School of Health Innovation, Kanagawa University of Human Services, Kanagawa, Japan

3. Department of Hematology, Osaka International Cancer Institute, Osaka, Japan

4. CRECON Medical Assessment Inc., Tokyo, Japan

5. Aichi Cancer Center, Aichi, Japan

Funder

Chugai Pharmaceutical Co., Ltd

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2254162

Reference34 articles.

1. The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities

2. Relapsed/Refractory Diffuse Large B-Cell Lymphoma

3. Japanese Society of Hematology. Zōketsukishuyō shinryō gaidorain [Practical guidelines for hematological malignancies]; 2018 [cited 2023 Mar 28]. Available from: http://www.jshem.or.jp/gui-hemali/table.html

4. Diagnosis and Management of Diffuse Large B-Cell Lymphoma: Society of Medical Oncology, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline

5. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma